Vistagen therapeutics.

Based on 1 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $12.00 with a high ...The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. VistaGen ...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2

Vistagen is currently evaluating the path forward for PH284, including assessing studies Vistagen believes will be necessary to submit a U.S. IND for further Phase 2 clinical development of PH284, on its own or with collaborators, as well as evaluating the appropriate patient populations for demonstrating an increase in appetite and weight gain.Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those …

VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.

Vistagen Pipeline (Vistagen) The company’s lead program, Fasedienol (PH94B), is a neuroactive nasal spray that could potentially be a breakthrough in the management of social anxiety disorder (SAD).Vistagen Therapeutics, Inc. (NASDAQ:NASDAQ:VTGN) Q3 2024 Earnings Conference Call February 13, 2024 5:00 PM ETCompany ParticipantsMark McPartland - Senior...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited)VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders.

Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging ...

VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets:

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the ...Aug 11, 2022 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care in large markets for treatment ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company pioneering …Itruvone is an odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action (MOA) for the potential treatment of major depressive disorder (MDD). Itruvone’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen's six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful ...

Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.Walk-in tubs have become increasingly popular among seniors for their safety features and therapeutic benefits. However, one important consideration when purchasing a walk-in tub i...VistaGen Therapeutics (NASDAQ:VTGN) shares have completed a remarkable turnaround over the past 6 months. In October last year, the company was granted a 180-day extension to regain compliance ...About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to … Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed mechanism of action (MOA) of fasedienol is novel and ... Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen’s six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful ...

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .

Discover real-time Vistagen Therapeutics, Inc. Common Stock (VTGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or ...About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to …Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets:Apr 16, 2024 · The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. About VistaGen Therapeutics. VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. Drug rescue involves the combination of human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants of once-promising small molecule …

VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder. SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 /PRNewswire/ -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central …

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a …

Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Amount of Analyst Coverage. Vistagen Therapeutics has received no research coverage in the past 90 days. Read more about Vistagen Therapeutics' stock forecast and price ... Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed mechanism of action (MOA) of fasedienol is novel and ... Ester Salmán, MPH, joined Vistagen in May 2021 and currently serves as Vice President, Clinical Research. She brings extensive experience in steering the clinical, scientific, and strategic aspects of ongoing clinical programs, ensuring alignment with organizational goals. 6 days ago · Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ... Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, …In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in r...VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns ...(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of VistaGen Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, and the rules and regulations thereunder;VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with topline results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder.About VistaGen Therapeutics. VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern …

As we age, it’s important to keep our minds sharp and engaged. One way to do this is by participating in crossword puzzles. Not only are they a fun and enjoyable activity, but they...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...VistaGen Therapeutics is a late-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's clinical-stage drug candidates has therapeutic potential in multiple CNS …About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to …Instagram:https://instagram. the cut the ropeplane tickets to dallas from laxnova a.i.get stuff done Aug 11, 2022 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) Feb 6, 2024 · Press Releases. Year. All Years. Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference. May 07, 2024. Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue. Apr 25, 2024. Vistagen to Present at the 2024 Anxiety and Depression ... washington dc to orlandowashington metro rail map VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript February 13, 2024 VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. element smart tv Significant control over Vistagen Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders ...The average VistaGen Therapeutics salary ranges from approximately $74342 per year for Office Manager to $253783 per year for Vice President.Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080. Tel: (650) 577-3600 Fax: (888) 482-2602